| [1] PubMed ID: | 39343854 |
| Disease Name: | Primary Ovarian Insufficiency |
| Tissue: | Ovary |
| Dysfunction Pattern: | N/A |
| Validated Method: | RT-PCR//Western blot//ELISA//High-throughput sequencing |
| Description: | In this study, we revealed a novel molecular mechanism by which tsRNA-3043a promotes POF via inhibiting FLT1(Fig. 10). Targeting tsRNA-3043a may be a novel strategy for pharmacological treatment of POF. |
| Comparision: | Disease VS Control |
| Mechanism: | TsRNAs are small regulatory non-code RNAs that cleavage from mature tRNA or precursor tRNA, which exert biological roles through multiple mechanisms, including interaction with proteins or mRNA, repression of translation, regulation of gene expression, chromatin and epigenetic modifications (Xie et al. 2020). However, only three studies on “tsRNA ovarian” were retrieved from the PubMed. One of them was a comprehensive analysis of non-coding RNAs in the ovarian of Onychostoma macrolepis in the late overwintering and breeding period, and identified 235 differentially expressed tsRNAs, including tRFi-Lys-CTT-1 and tRFi-Gly-GCC-1(Peng et al. 2022). Secondly, Panoutsopoulou et al. Found that i-tRF-GlyGCC expression was abundant in ovarian tumors and can be used for prognostic assessment of patients with epithelial ovarian cancer (Panoutsopoulou et al. 2021). Thirdly, Panoutsopoulou et al. Demonstrated that the 3’U-tRFValCAC promotes a malignant phenotype in ovarian cancer (Panoutsopoulou et al. 2023). Although these three studies are different from the mechanism of POF, they may strongly confirm that tsRNAs play an important role in the pathology of ovarian. In addition, tsRNAs are often thought to play similar roles to miRNAs in a manner of “miRNA-like” (Krishna et al. 2021). |
|